News
Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...
A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...
While the makers of Ozempic have stated that its GLP-1 medication was not made to be used as a weight loss drug, nor should ...
1h
Stocktwits on MSNNovo Nordisk Gains Ground In Obesity Race As Amycretin, Wegovy Show Significant Weight LossNovo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...
4d
Zacks.com on MSNCan Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market ...
GLP-1 drugs like Ozempic and Wegovy change food cravings and taste preferences—leading to weight loss beyond just reduced ...
Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...
A trial pitting weight loss jab Mounjaro against competitor Wegovy ended with one clear winner, and Mounjaro is getting ...
Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those ...
While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...
A federal judge on Wednesday ruled that the Food and Drug Administration’s (FDA) decision to remove popular GLP-1s from its drug shortage list, ending the sale of compounded versions of the ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results